AI ScreeningAI ChatPricing
  1. JP-listed companies
  2. CellSource Co.,Ltd.
  3. Financials
  4. EBITDA margin (%)

CellSource Co.,Ltd.【JP:4880】

Market cap
¥7.5B
P/E ratio
-54.8x
CellSource processes blood and fat tissue into therapeutic substances for medical institutions offering regenerative medicine treatments like knee osteoarthritis and infertility care.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndEBITDA margin (%) YoY (%)
Oct 31, 20259.8+57.94%
Oct 31, 20246.2-78.15%
Oct 31, 202328.5-24.66%
Oct 31, 202237.8+8.04%
Oct 31, 202135+47.01%
Oct 31, 202023.8+10.38%
Oct 31, 201921.6-15.17%
Oct 31, 201825.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)